Ad hoc: Biofrontera AG: Ameluz® Cooperation Agreement for Slovenia with PHA FARMED Consultancy s.p.
(Thomson Reuters ONE) -
Biofrontera AG /
Misc. matters /
Ad hoc: Biofrontera AG: Ameluz® Cooperation Agreement for Slovenia with PHA
FARMED Consultancy s.p.
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, 22 February 2013 - Biofrontera Pharma GmbH, a fully-owned subsidiary
of Biofrontera AG, has today signed an exclusive agreement with PHA Farmed s.p.,
Ljubljana, for the marketing of Ameluz(®) in Slovenia. In December 2011
Ameluz(®) received a centralized European approval as prescription medicinal
product for the first-line treatment of mild and moderate actinic keratosis in
the face and on the scalp.
To assure the efficient and successful penetration of the Slovenian market with
Ameluz(®) PHA Farmed provides fully integrated expert solutions as strategic
partnership at all stages of the pharmaceutical business process.
PHA Farmed will support Biofrontera in the marketing of Ameluz(®) in Slovenia, a
market in which German or English labeling on tubes and packages is accepted
upon application. Biofrontera will thus be able to sell Ameluz(®) without the
need for separate manufacturing to a local wholesaler for further distribution.
All activities and costs related to marketing and sales, local reimbursement and
pricing negotiations, and local pharmacovigilance will be taken on by PHA
Farmed. In return, PHA Farmed will receive 40% of the revenues that Biofrontera
achieves in this Territory with Ameluz(®).
Ameluz(®) is used in the treatment of actinic keratosis, a superficial skin
cancer, by photodynamic therapy (PDT). The treatment combines Ameluz(®) with a
strong red light illumination, provided f.i. through Biofrontera's BF-
RhodoLED(®) lamp, the marketing of which is also ruled by the agreement between
the two companies.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact:
Anke zur Mühlen
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail: a.zurmuehlen(at)biofrontera.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1680388]
Unternehmensinformation / Kurzprofil:
Datum: 22.02.2013 - 12:32 Uhr
Sprache: Deutsch
News-ID 232332
Anzahl Zeichen: 2889
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 100 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ad hoc: Biofrontera AG: Ameluz® Cooperation Agreement for Slovenia with PHA FARMED Consultancy s.p."
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
